What is the Dishman Carbogen Amcis PE ratio today?
Dishman Carbogen Amcis' PE ratio is 145.0 at the 29 October 2026 close (₹149.42 a share): a market capitalisation of ₹2,343 crore divided by consolidated net profit of ₹16.2 crore over the last four quarters (Q2 FY26 to Q1 FY27). On FY26 net profit (₹97.5 crore) it is 24.0.
What is the Dishman Carbogen Amcis net worth?
Dishman Carbogen Amcis' net worth — shareholders' equity in its consolidated balance sheet — was ₹6,677 crore on 31 March 2026, up 14.5% from ₹5,832 crore a year earlier. Its market value is a different figure: a market capitalisation of ₹2,343 crore at the 29 October 2026 close.
What is the Dishman Carbogen Amcis book value per share?
Dishman Carbogen Amcis' book value per share was ₹425.82 on 31 March 2026: shareholders' equity of ₹6,677 crore divided by the 15.68 crore shares in issue, up 14.5% from ₹371.91 a year earlier. The share price at the 29 October 2026 close was ₹149.42.
What is the Dishman Carbogen Amcis PB ratio (price to book value)?
Dishman Carbogen Amcis' price-to-book (PB) ratio is 0.35 at the 29 October 2026 close: a market capitalisation of ₹2,343 crore divided by shareholders' equity (book value) of ₹6,677 crore on 31 March 2026. That is a book value of ₹425.82 per share against a share price of ₹149.42.
What is the Dishman Carbogen Amcis ROE and ROCE?
In FY26, Dishman Carbogen Amcis' return on equity (ROE) was 1.6% and its return on capital employed (ROCE) was 2.6%. ROE is net profit divided by average shareholders' equity (the start and end of the year); ROCE is operating profit (EBIT) divided by average capital employed (total assets less current liabilities). In FY25, ROE was 0.1% and ROCE 2.3%.
What is the Dishman Carbogen Amcis shareholding pattern?
On 30 September 2026, Dishman Carbogen Amcis' shares were held by promoters 59.32%, foreign portfolio investors (FII/FPI) 6.97%, domestic institutions (DII) 1.66% (including mutual funds at 1.41%) and retail and other non-institutional investors 32.06%. Over the year, FII holding was down 1.10 percentage points from 8.07% and DII holding was up 0.29 percentage points from 1.37%.
What is the Dishman Carbogen Amcis market cap?
Dishman Carbogen Amcis' market capitalisation was ₹2,343 crore at the 29 October 2026 close: 15.68 crore shares at ₹149.42 each.
What is the Dishman Carbogen Amcis EPS?
Dishman Carbogen Amcis' basic earnings per share (EPS) were ₹6.22 in FY26, against ₹0.21 in FY25. Over the last four quarters (Q2 FY26 to Q1 FY27) they add up to ₹1.03.
What is the Dishman Carbogen Amcis revenue and profit in FY26?
In FY26 (April 2025–March 2026), Dishman Carbogen Amcis' consolidated net profit was ₹97.5 crore, null, on revenue from operations of ₹2,932 crore (up 8.1%).
Is Dishman Carbogen Amcis debt free?
No. Dishman Carbogen Amcis had borrowings of ₹2,775 crore on 31 March 2026 (consolidated balance sheet), a debt-to-equity ratio of 0.42. Its cash and current investments were ₹1,007 crore, so its net debt was ₹1,768 crore.
What is the Dishman Carbogen Amcis debt to equity ratio?
Dishman Carbogen Amcis' debt-to-equity ratio was 0.42 on 31 March 2026: borrowings of ₹2,775 crore against total equity of ₹6,677 crore. A year earlier, on 31 March 2025, it was 0.36.
What is the Dishman Carbogen Amcis promoter holding?
Promoters held 59.32% of Dishman Carbogen Amcis on 30 September 2026, unchanged from both the previous quarter and a year earlier, according to the shareholding pattern filed with NSE.
What is the Dishman Carbogen Amcis free cash flow?
In FY26, Dishman Carbogen Amcis generated ₹491 crore of cash from operations and spent ₹266 crore on capital expenditure (property, plant, equipment and intangibles), leaving free cash flow of ₹225 crore. In FY25 it was ₹158 crore.
What are the Dishman Carbogen Amcis latest quarterly results?
Dishman Carbogen Amcis' latest results are for Q1 FY27 (April–June 2026), filed on 14 August 2026: consolidated net loss ₹57.9 crore, against a profit of ₹23.4 crore in Q1 FY26; revenue from operations ₹678 crore, down 4.3% year on year.
When are the Dishman Carbogen Amcis next results?
Dishman Carbogen Amcis has not yet announced the date of its Q2 FY27 results (July–September 2026); under SEBI's listing rules (Regulation 33) they are due by 14 November 2026.
How does Dishman Carbogen Amcis compare with its peers?
On FY26 consolidated figures, against Hikal, Solara Active Pharma Sciences and Panacea Biotec: Dishman Carbogen Amcis' operating margin of 7.7% is the highest of the four (Hikal 3.3%, Solara Active Pharma Sciences 6.4%, Panacea Biotec −5.9%; peer average 1.3%); its return on equity of 1.6% is the highest of the four (Hikal −4.0%, Solara Active Pharma Sciences −0.6%, Panacea Biotec −0.6%; peer average −1.7%); its revenue growth over three years of 6.7% a year is the second highest of the four (Hikal −5.4% a year, Solara Active Pharma Sciences −1.8% a year, Panacea Biotec 11.6% a year; peer average 1.5% a year).
Dishman Carbogen Amcis vs Hikal: how do they compare?
In FY26, Dishman Carbogen Amcis earned net profit of ₹97.5 crore on revenue of ₹2,932 crore, against ₹48.8 crore on ₹1,713 crore for Hikal. Dishman Carbogen Amcis' operating margin was 7.7% (Hikal 3.3%) and its return on equity 1.6% (Hikal −4.0%). At the 29 October 2026 close, Dishman Carbogen Amcis' market capitalisation was ₹2,343 crore against ₹2,524 crore for Hikal.
Consolidated figures from the company's filings with NSE; prices are NSE closing prices.
